Spectrum Pharmaceuticals Submits Data To FDA In Support Of Bioscan Removal For ZEVALIN(R)
Links shared publicly online about this topic.
- 553total visits
Spectrum Pharmaceuticals Submits Data To FDA In Support Of Bioscan Removal For ZEVALIN(R)
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced that on Thursday, J
View full resource at medicalnewstoday.com
Tags: Drug, Pharma, Biotech, FDA, Oncology, Surgery
Most Recently Shared on January 26, 2011 at 3:05 pm By:
Spectrum Pharmaceuticals Submits Data To FDA In Support Of Bioscan Removal For ZEVALIN(R) http://mnt.to/3QrR #regulatory
Also Shared By:
StreetInsider.com - Spectrum Pharmaceuticals Submits Data to FDA in Support of Bioscan Removal for ZEVALIN®
streetinsider.com — “StreetInsider.com - Spectrum Pharmaceuticals Submits Data to FDA in Support of Bioscan Removal for ZEVALIN®” View full resource at streetinsider.com
Most Recently Shared on January 25, 2011 at 12:03 am By:
JanCerny, MD, PhD Physician, Doctor, PhD, Internist, Oncologist, and Hematologist
Spectrum Pharmaceuticals Submits Data to FDA in Support of Bioscan Removal for ZEVALIN® http://ow.ly/3Ju0q
Advertisement
MNT Leukemia
@mnt_leukemia
Spectrum Pharmaceuticals Submits Data To FDA In Support Of Bioscan Removal For ZEVALIN(R) http://mnt.to/3QrR #lymphoma #leukemia
1 year ago...